571 Results (Page 2 of 23)
Spain Markets Research Reports
Spain Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis
Spain Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc
Spain Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis
Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.
Spain Clinical Nutrition for Cancer Care Market Analysis
The Spain Clinical Nutrition for Cancer Care Market was valued at $108.7 Mn in 2023 and is predicted to grow at a CAGR of 4.04% from 2023 to 2030, to $143.4 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Spain Clinical Nutrition for Cancer Care Market are Fresenius Kabi España, Baxter España, and Clinical Nutrition SAU, among others.
Spain Gram-Negative Infection Therapeutics Market Analysis
The Spain Gram-Negative Infection Therapeutics Market was valued at $287.1 Mn in 2023 and is predicted to grow at a CAGR of 4.9% from 2023 to 2030 to $401.3 Mn by 2030. Factors fuelling this market expansion include the aging population, heightened research and development efforts, and the increasing prevalence of gram-negative infections. Leading companies in this market include Sanofi, Novartis, Baxter, Takeda, and others.
Spain Home Infusion Therapy Market
The Spain Home Infusion Therapy Market was valued at $694 Mn in 2023 and is predicted to grow at a CAGR of 7.1% from 2023 to 2030, to $1121.8 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the Spain Home Infusion Therapy Market are Becton, Dickinson and Company (BD), Baxter International, ICU Medical (Smiths Medical), and Fresenius Kabi, among others.
Spain Hepatitis A Therapeutics Market Analysis
The Spain Hepatitis A Therapeutics Market was valued at $14.23 Mn in 2023 and is predicted to grow at a CAGR of 1.2% from 2023 to 2030 to $15.27 Mn by 2030. Significant factors driving this market include the rising prevalence of Hepatitis A in Spain, the growing vulnerable population, and Spain's global health initiatives. Leading companies in this sector, such as F. Hoffmann-La Roche Ltd. and Grifols, play significant roles.
Spain Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis
Spain Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.
Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market Analysis
Spain Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS) are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
Spain Myeloproliferative Disorders (MPD) Therapeutics Market Analysis
Spain Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.
Spain Digital Health Market Analysis
The Spain Digital Health market is projected to grow from $ 4.07Bn in 2022 to $ 14.9Bn by 2030, registering a CAGR of 17.6%% during the forecast period of 2022 - 2030. The market is driven by the emergence of new technologies and the increasing population with a growing demand for digital health. The market is segmented by solution, by deployment & by end-use. Some of the major players include Medtep, Nubentos& SaludOnNet.
Spain Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis
Spain Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.
Spain Spinal Muscular Atrophy (SMA) Therapeutics Market Analysis
Spain's Spinal Muscular Atrophy (SMA) Therapeutics Market is projected to grow from $89.2 Mn in 2022 to $337.58 Mn by 2030, registering a CAGR of 18.1% during the forecast period of 2022-2030. The market is expanding as a result of rising SMA instances, technological advancements, government encouragement, rising consumer awareness, and increased R&D activities. Major global players in Spinal Muscular Atrophy (SMA) Therapeutics Market are Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Boehringer Ingelheim International GmbH. (Germany), GSK plc (U.K.), Novartis AG (Switzerland), Biogen (U.S.), Pfizer Inc.(U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Regeneron Pharmaceuticals Inc (U.S.)., Abbott (U.S.), AbbVie Inc. (U.S.), Novo Nordisk A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca (U.K.), Leadiant Biosciences, Inc.(Italy), Catalyst Pharmaceuticals, Inc.(U.S.), PTC Therapeutics (U.S.)
Spain Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
Spain's Myelodysplastic Syndrome (MDS) therapeutics market is projected to grow from $43.8 Mn in 2022 to $82.28 Mn by 2030, registering a CAGR of 8.2% during the forecast period of 2022-30. The market for pharmaceuticals for myelodysplastic syndrome (MDS) is growing as a result of a number of factors, including a rise in pediatric population, improved awareness, the launch of novel drugs, government initiatives to provide target-specific therapy, and favourable reimbursement policies. Major global players in this market are Abbott, Boehringer Ingelheim International GmbH, Johnson & Johnson Private Limited, MEI Pharma Inc., MTW Endoskopie Manufaktur, Aprea Therapeutics, Dr. Reddy's Laboratories Ltd, AbbVie Inc., Acceleron Pharma, Inc., Mylan N.V., Bristol-Myers Squibb Company, Eisai Co., Ltd., and LGM Pharma are a few other companies that are involved in the pharmaceutical industry.
Spain Lymphoma Therapeutics Market Analysis
Spain's Lymphoma Therapeutics Market was valued at $8.33 Mn in 2023 and is predicted to grow at a CAGR of 8.90 % from 2023 to 2030, to $15.13 Mn by 2030. The key drivers of this industry include the rising prevalence of lymphoma, the aging population, advancements in treatment, increased awareness, and early detection. The industry is primarily dominated by Bristol Myers Squibb Company, F. Hoffmann-La Roche, AbbVie, and Johnson & Johnson among others.
Spain Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Analysis
This report presents a strategic analysis of the Spain Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Spain Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy and expert insights.
Spain Over The Counter (OTC) Analgesics Market Analysis
This report presents a strategic analysis of the Spain Over The Counter (OTC) Analgesics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Spain Over The Counter (OTC) Analgesics Market, offering unmatched value, accuracy and expert insights.
Spain Nutritional Supplements Market Analysis
By 2030, it is anticipated that the Spain Nutrition and Supplements market will reach a value of $13.13 Bn from $7.36 Bn in 2022, growing at a CAGR of 7.5% during 2022-2030. The market is primarily dominated by local players such as Bioderma, Herbes del Món, and Naturhouse. The market for nutrition and supplements in Spain is primarily driven by reimbursement scenarios, access to pharmacies, and traditional supplement businesses. The Spain nutrition and supplements market in Spain is segmented by Type, Product, application, and Distribution Channel.
Spain Conjunctivitis Therapeutics Market Analysis
The Spain Conjunctivitis Therapeutics Market was valued at $79 Mn in 2022 and is predicted to grow at a CAGR of 4.4% from 2023 to 2030, to $112 Mn by 2030. The key drivers of this industry include the increasing burden of conjunctivitis, the development of new therapeutics in the industry, and expanding healthcare infrastructure. The industry is primarily dominated by players such as Allergan, Pfizer, Bausch & Lomb, Merck, Santen, Novartis, and Sanofi among others.
Spain Artificial Intelligence (AI) in Diagnostics Market Analysis
Spain's Artificial Intelligence (AI) in the diagnostics market is projected to grow from $0.02 Bn in 2022 to $0.20 Bn by 2030, registering a CAGR of 34% during the forecast period of 2022-30. The market will be driven by increasing demand for more accurate and efficient diagnostic solutions and positive government initiatives. The market is segmented by component & by diagnosis. Some of the major players include GE Healthcare, IBM Watson Health & QUIBIM.
Spain Artificial Intelligence (AI) in Medical Imaging Market Analysis
The Spain Artificial Intelligence (AI) in Medical Imaging market size was valued at $29 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 34.4% from 2022 to 2030 and will reach $308 Mn. The market is segmented by AI technology, solution, modality, application, and end User. The Spain Artificial Intelligence (AI) in the Medical Imaging market will grow due to advances in AI and machine learning algorithms that are making it possible to develop more accurate and efficient medical imaging software. Some of the key players in this market are Siemens Healthineers, Philips Healthcare, Agfa-Gevaert Group, Canon Medical Systems, Fujifilm, Samsung Healthcare, Brainlab, IBM Watson Health, Sectra, Arterys, and others.
Spain Neuroendocrine Tumor Therapeutics Market Analysis
Spain neuroendocrine tumor therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for neuroendocrine tumors is being driven by an increase in the number of cases of these tumors. Major global players in this market are F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG.
Spain Complex Regional Pain Syndrome (CRPS) Market Analysis
Spain Complex regional pain syndrome (CRPS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Complex regional pain syndrome (CRPS) is expanding as a result of rising incidence of complex regional pain syndrome and the growing number of patients suffering from chronic pain and failing back syndrome. Growth in R&D spending by both commercial and public institutions, as well as favourable government legislation and increase in product launches are other factors increasing market growth. Ovid therapeutics, Astra Zeneca, Abbott, GSK, Viatris and Johnson & Johnson Services are the top key market players in Global Complex regional pain syndrome (CRPS) market.
Spain Cholesterol Therapeutics Market Analysis
The Spain Cholesterol Therapeutics Market is anticipated to experience a growth from $469 Mn in 2022 to $532 Mn by 2030, with a CAGR of 1.6% during the forecast period of 2022-2030. The presence of prominent active pharmaceutical companies, coupled with the conducive environment fostered by ongoing research and therapeutic advancements, and the increased prevalence due to demographics and social factors further contribute to the dynamic growth of the market in Spain. The Spain Cholesterol Therapeutics Market encompasses various players across different segments such as Pfizer, Merck, Roche, Novartis, AstraZeneca, Johnson & Johnson, Almirall, Bayer, Grifol, PharmaMar, etc., among various others.
Spain Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis
Spain Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.
Spain Liver Disease Drugs Market Analysis
This report presents a strategic analysis of the Spain Liver Disease Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Spain Liver Disease Drugs Market, offering unmatched value, accuracy and expert insights.